Kura Oncology, Inc. (KURA)
NASDAQ: KURA · Real-Time Price · USD
10.27
-0.17 (-1.63%)
At close: Oct 31, 2025, 4:00 PM EDT
10.45
+0.18 (1.75%)
After-hours: Oct 31, 2025, 7:45 PM EDT
Kura Oncology Revenue
Kura Oncology had revenue of $15.29M in the quarter ending June 30, 2025. This brings the company's revenue in the last twelve months to $83.28M. In the year 2024, Kura Oncology had annual revenue of $53.88M.
Revenue (ttm)
$83.28M
Revenue Growth
n/a
P/S Ratio
10.76
Revenue / Employee
$433,745
Employees
192
Market Cap
891.41M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 53.88M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 56.50B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.11B |
KURA News
- 3 days ago - Kura Oncology to Report Third Quarter 2025 Financial Results - GlobeNewsWire
- 7 days ago - Kura Oncology Receives $30 Million Development Milestone Payment in Ziftomenib AML Program with Kyowa Kirin - GlobeNewsWire
- 13 days ago - Kura Oncology, Inc. (KURA) Discusses Clinical Updates on Farnesyl Transferase Inhibitor Programs and Combination Therapies in Oncology Transcript - Seeking Alpha
- 13 days ago - Kura Oncology Announces Preliminary Data from Its Farnesyl Transferase Inhibitor (FTI) Programs at the 2025 European Society for Medical Oncology (ESMO) Congress - GlobeNewsWire
- 4 weeks ago - Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - Kura Oncology, Inc. (KURA) Presents at UBS Virtual Oncology Day Transcript - Seeking Alpha
- 4 weeks ago - Kura Oncology and Kyowa Kirin Launch Clinical Trial Evaluating Dual Inhibition of NPM1 and FLT3 Mutations in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) - GlobeNewsWire
- 4 weeks ago - Kura Oncology and Kyowa Kirin Announce First Patient Dosed in Pivotal Phase 3 KOMET-017 Trial of Ziftomenib for Frontline Acute Myeloid Leukemia (AML) - GlobeNewsWire